900841
Poly(ethylene glycol) methyl ether-block-poly(lactide-co-glycolide)
PEG average Mn 5,000, PLGA Mn 5,000, lactide:glycolide 80:20
Synonym(s):
PEG-PLGA, Polyethylene glycol, mPEG-b-PLGA
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
Linear Formula:
H[(C3H4O2)x(C2H2O2)y]mO[C2H4O]nCH3
UNSPSC Code:
51171641
form
powder
feed ratio
lactide:glycolide 80:20
mol wt
PEG average Mn 5,000
PLGA Mn 5,000
impurities
≤5000 ppm (GC)
shipped in
dry ice
storage temp.
−20°C
Looking for similar products? Visit Product Comparison Guide
General description
Contains ≤500 ppm impurities by GC, including trace monomer and residual organics.
Application
Biocompatible block copolymer. Can be used in the formation of nanoparticles for drug delivery. Potential use in the targeted and/or controlled release of cancer drugs, anti-inflammatory drugs, antibiotics, or anesthetic agents.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug.
Miller MA, et al.
Nature Communications, 6 (2015)
Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation.
Danhier F, et al.
J. Controlled Release, 133, 11-17 (2009)
Yihan Xu et al.
Journal of biomedical materials research. Part B, Applied biomaterials, 105(6), 1692-1716 (2016-04-22)
Poly (lactic-co-glycolic acid) (PLGA) copolymers have been broadly used in controlled drug release applications. Because these polymers are biodegradable, they provide an attractive option for drug delivery vehicles. There are a variety of material, processing, and physiological factors that impact
R Gref et al.
Science (New York, N.Y.), 263(5153), 1600-1603 (1994-03-18)
Injectable nanoparticulate carriers have important potential applications such as site-specific drug delivery or medical imaging. Conventional carriers, however, cannot generally be used because they are eliminated by the reticulo-endothelial system within seconds or minutes after intravenous injection. To address these
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service